This Medical Letter drug review summarizes a newly approved inhaled, rapid-acting formulation of recombinant human insulin for treatment of adults with type 1 or type 2 diabetes.
Wallia and Molitch review currently available insulin therapy, as well as evidence on the use, application, initiation, and intensification of insulin in the outpatient setting.
This pharmacoeconomic study uses MEPS data to compare trends in expenditure and price of antihyperglycemic medications in the United States from 2002 through 2013.
This Medical Letter review summarizes information about liraglutide, a GLP-1 receptor agonist approved for long-term weight weight management in adults with a body mass index (BMI) of 30 or greater, or in those with a BMI of 27 or greater plus weight-related comorbidity such as hypertension, dyslipidemia, or diabetes.
This Review summarizes advances in diagnosis and treatment of type 1 and type 2 diabetes between 2005 and 2015.
This randomized trial reports that, among overweight and obese participants with type 2 diabetes, use of daily liraglutide, a glucagon-like peptide 1 analog, resulted in weight loss over 56 weeks compared with placebo.